Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Jazz Pharmaceuticals plc
JAZZ
$229.19
Name : Jazz Pharmaceuticals plc
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $14,380,026,880.00
EPSttm : 0.12
finviz dynamic chart for JAZZ
Jazz Pharmaceuticals plc
$229.19
1.23%
$2.85
JAZZ — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

8.1

Margin Of Safety %

15

Put/Call OI Ratio

0.76

EPS Next Q Diff

0.9

EPS Last/This Y

31.07

EPS This/Next Y

0.5

Price

229.17

Target Price

257.83

Analyst Recom

1.57

Performance Q

23.27

Upside

-100.1%

Beta

0.33

Ticker: JAZZ




20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-05-11JAZZ223.580.620.4610086
2026-05-12JAZZ227.820.620.3110233
2026-05-13JAZZ232.270.630.3110326
2026-05-14JAZZ231.070.630.8010497
2026-05-15JAZZ228.770.640.0510738
2026-05-18JAZZ229.650.790.626681
2026-05-19JAZZ237.550.800.046715
2026-05-20JAZZ239.080.790.066767
2026-05-21JAZZ239.490.790.056760
2026-05-22JAZZ239.770.790.386754
2026-05-26JAZZ237.30.800.696759
2026-05-27JAZZ237.80.800.046787
2026-05-28JAZZ235.50.800.306810
2026-05-29JAZZ236.490.790.146864
2026-06-02JAZZ226.180.780.036966
2026-06-03JAZZ230.990.770.797041
2026-06-04JAZZ240.020.730.426894
2026-06-05JAZZ238.610.703.987110
2026-06-08JAZZ232.010.718.787142
2026-06-09JAZZ229.020.763.837382
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-05-11JAZZ223.57173.91145.224.88
2026-05-12JAZZ227.74174.21171.825.05
2026-05-13JAZZ232.40174.21173.525.32
2026-05-14JAZZ231.12174.21149.625.32
2026-05-15JAZZ228.63174.21144.425.32
2026-05-18JAZZ229.71174.21158.425.32
2026-05-19JAZZ237.45174.21186.525.32
2026-05-20JAZZ238.97174.21160.925.32
2026-05-21JAZZ239.48174.21156.625.32
2026-05-22JAZZ239.82174.21155.625.32
2026-05-26JAZZ237.44174.81145.425.21
2026-05-27JAZZ237.52174.81155.225.21
2026-05-28JAZZ235.33174.81145.525.21
2026-05-29JAZZ236.52174.81159.425.21
2026-06-01JAZZ232.67174.91139.025.23
2026-06-02JAZZ225.97174.91127.125.23
2026-06-03JAZZ230.98174.91174.925.23
2026-06-04JAZZ240.05174.91191.825.23
2026-06-05JAZZ238.57174.91148.725.23
2026-06-08JAZZ232.01174.91128.725.23
2026-06-09JAZZ229.17174.91143.125.23
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-05-11JAZZ-5.981.998.81
2026-05-12JAZZ-5.981.998.56
2026-05-13JAZZ-5.981.998.56
2026-05-14JAZZ-5.981.998.56
2026-05-15JAZZ-5.981.998.56
2026-05-18JAZZ-5.980.888.55
2026-05-19JAZZ-6.100.888.55
2026-05-20JAZZ-5.900.888.55
2026-05-21JAZZ-5.100.888.55
2026-05-22JAZZ-5.100.888.55
2026-05-26JAZZ-5.016.388.50
2026-05-27JAZZ-5.606.388.50
2026-05-28JAZZ-5.756.388.10
2026-05-29JAZZ-5.756.388.10
2026-06-02JAZZ-3.555.578.10
2026-06-03JAZZ-3.565.578.10
2026-06-04JAZZ-3.755.578.10
2026-06-05JAZZ-3.755.578.10
2026-06-08JAZZ-3.755.588.10
2026-06-09JAZZ-3.755.588.10
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

5.46

Avg. EPS Est. Current Quarter

6.18

Avg. EPS Est. Next Quarter

6.36

Insider Transactions

-3.75

Institutional Transactions

5.58

Beta

0.33

Average Sales Estimate Current Quarter

1112

Average Sales Estimate Next Quarter

1151

Fair Value

263.3

Quality Score

57

Growth Score

82

Sentiment Score

83

Actual DrawDown %

5.8

Max Drawdown 5-Year %

-47.5

Target Price

257.83

P/E

Forward P/E

8.91

PEG

0.17

P/S

3.24

P/B

3.17

P/Free Cash Flow

11.33

EPS

-0.02

Average EPS Est. Cur. Y​

25.23

EPS Next Y. (Est.)

25.73

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

0.66

Relative Volume

0.78

Return on Equity vs Sector %

-26.8

Return on Equity vs Industry %

-10.7

EPS 1 7Days Diff

EPS 1 30Days Diff

1.15

EBIT Estimation

1143.1
JAZZ Healthcare
$229.19
📉
Swing / Pullback
Buy the dip on strong trends
44 /100
WEAK
Trend
2/20
Pullback
15/25
Volume
9/15
Valuation
12/20
TP/AR
3/10
Options
3/10
RSI
51.8
Range 1M
36.9%
Sup Dist
0.1%
🚀
Momentum Growth
Ride accelerating trends
N/A
47 /100
WEAK
Momentum
6/25
Growth
21/30
Estimates
6/20
Inst/Vol
9/15
Options
5/10
EPS Yr
202.7%
EPS NY
1.4%
52W%
89.9%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟡 HOLD +29.9% upside
Quality
8/30
Valuation
16/30
Growth
17/25
Stability
6/10
LT Trend
1/5
Upside
+29.9%
Quality
57
MoS
15%
Jazz Pharmaceuticals plc
Sector: Healthcare
Industry: Biotechnology
Employees: 2890
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
JAZZ

Latest News

Caricamento notizie per JAZZ
stock quote shares JAZZ – Jazz Pharmaceuticals plc Stock Price stock today
news today JAZZ – Jazz Pharmaceuticals plc stock forecast ,stock prediction 2023 2024 2025
marketwatch JAZZ – Jazz Pharmaceuticals plc yahoo finance google finance
stock history JAZZ – Jazz Pharmaceuticals plc invest stock market
stock prices JAZZ premarket after hours
ticker JAZZ fair value insiders trading
Jazz Pharmaceuticals plc
JAZZ
$229.19
Name : Jazz Pharmaceuticals plc
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $14,380,026,880.00
EPSttm : 0.12
finviz dynamic chart for JAZZ
Jazz Pharmaceuticals plc
$229.19
1.23%
$2.85
JAZZ — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

8.1

Margin Of Safety %

15

Put/Call OI Ratio

0.76

EPS Next Q Diff

0.9

EPS Last/This Y

31.07

EPS This/Next Y

0.5

Price

229.17

Target Price

257.83

Analyst Recom

1.57

Performance Q

23.27

Upside

-100.1%

Beta

0.33

Ticker: JAZZ




20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-05-11JAZZ223.580.620.4610086
2026-05-12JAZZ227.820.620.3110233
2026-05-13JAZZ232.270.630.3110326
2026-05-14JAZZ231.070.630.8010497
2026-05-15JAZZ228.770.640.0510738
2026-05-18JAZZ229.650.790.626681
2026-05-19JAZZ237.550.800.046715
2026-05-20JAZZ239.080.790.066767
2026-05-21JAZZ239.490.790.056760
2026-05-22JAZZ239.770.790.386754
2026-05-26JAZZ237.30.800.696759
2026-05-27JAZZ237.80.800.046787
2026-05-28JAZZ235.50.800.306810
2026-05-29JAZZ236.490.790.146864
2026-06-02JAZZ226.180.780.036966
2026-06-03JAZZ230.990.770.797041
2026-06-04JAZZ240.020.730.426894
2026-06-05JAZZ238.610.703.987110
2026-06-08JAZZ232.010.718.787142
2026-06-09JAZZ229.020.763.837382
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-05-11JAZZ223.57173.91145.224.88
2026-05-12JAZZ227.74174.21171.825.05
2026-05-13JAZZ232.40174.21173.525.32
2026-05-14JAZZ231.12174.21149.625.32
2026-05-15JAZZ228.63174.21144.425.32
2026-05-18JAZZ229.71174.21158.425.32
2026-05-19JAZZ237.45174.21186.525.32
2026-05-20JAZZ238.97174.21160.925.32
2026-05-21JAZZ239.48174.21156.625.32
2026-05-22JAZZ239.82174.21155.625.32
2026-05-26JAZZ237.44174.81145.425.21
2026-05-27JAZZ237.52174.81155.225.21
2026-05-28JAZZ235.33174.81145.525.21
2026-05-29JAZZ236.52174.81159.425.21
2026-06-01JAZZ232.67174.91139.025.23
2026-06-02JAZZ225.97174.91127.125.23
2026-06-03JAZZ230.98174.91174.925.23
2026-06-04JAZZ240.05174.91191.825.23
2026-06-05JAZZ238.57174.91148.725.23
2026-06-08JAZZ232.01174.91128.725.23
2026-06-09JAZZ229.17174.91143.125.23
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-05-11JAZZ-5.981.998.81
2026-05-12JAZZ-5.981.998.56
2026-05-13JAZZ-5.981.998.56
2026-05-14JAZZ-5.981.998.56
2026-05-15JAZZ-5.981.998.56
2026-05-18JAZZ-5.980.888.55
2026-05-19JAZZ-6.100.888.55
2026-05-20JAZZ-5.900.888.55
2026-05-21JAZZ-5.100.888.55
2026-05-22JAZZ-5.100.888.55
2026-05-26JAZZ-5.016.388.50
2026-05-27JAZZ-5.606.388.50
2026-05-28JAZZ-5.756.388.10
2026-05-29JAZZ-5.756.388.10
2026-06-02JAZZ-3.555.578.10
2026-06-03JAZZ-3.565.578.10
2026-06-04JAZZ-3.755.578.10
2026-06-05JAZZ-3.755.578.10
2026-06-08JAZZ-3.755.588.10
2026-06-09JAZZ-3.755.588.10
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

5.46

Avg. EPS Est. Current Quarter

6.18

Avg. EPS Est. Next Quarter

6.36

Insider Transactions

-3.75

Institutional Transactions

5.58

Beta

0.33

Average Sales Estimate Current Quarter

1112

Average Sales Estimate Next Quarter

1151

Fair Value

263.3

Quality Score

57

Growth Score

82

Sentiment Score

83

Actual DrawDown %

5.8

Max Drawdown 5-Year %

-47.5

Target Price

257.83

P/E

Forward P/E

8.91

PEG

0.17

P/S

3.24

P/B

3.17

P/Free Cash Flow

11.33

EPS

-0.02

Average EPS Est. Cur. Y​

25.23

EPS Next Y. (Est.)

25.73

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

0.66

Relative Volume

0.78

Return on Equity vs Sector %

-26.8

Return on Equity vs Industry %

-10.7

EPS 1 7Days Diff

EPS 1 30Days Diff

1.15

EBIT Estimation

1143.1
JAZZ Healthcare
$229.19
📉
Swing / Pullback
Buy the dip on strong trends
44 /100
WEAK
Trend
2/20
Pullback
15/25
Volume
9/15
Valuation
12/20
TP/AR
3/10
Options
3/10
RSI
51.8
Range 1M
36.9%
Sup Dist
0.1%
🚀
Momentum Growth
Ride accelerating trends
N/A
47 /100
WEAK
Momentum
6/25
Growth
21/30
Estimates
6/20
Inst/Vol
9/15
Options
5/10
EPS Yr
202.7%
EPS NY
1.4%
52W%
89.9%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟡 HOLD +29.9% upside
Quality
8/30
Valuation
16/30
Growth
17/25
Stability
6/10
LT Trend
1/5
Upside
+29.9%
Quality
57
MoS
15%
Jazz Pharmaceuticals plc
Sector: Healthcare
Industry: Biotechnology
Employees: 2890
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
JAZZ

Latest News

Caricamento notizie per JAZZ
stock quote shares JAZZ – Jazz Pharmaceuticals plc Stock Price stock today
news today JAZZ – Jazz Pharmaceuticals plc stock forecast ,stock prediction 2023 2024 2025
marketwatch JAZZ – Jazz Pharmaceuticals plc yahoo finance google finance
stock history JAZZ – Jazz Pharmaceuticals plc invest stock market
stock prices JAZZ premarket after hours
ticker JAZZ fair value insiders trading